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Abstract: The aim of the present study is to present the different reactivity of azi-
thromycin and clarithromycin (pure and commercial) at a gold electrode in neutral 
electrolyte using cyclic linear sweep voltammetry under the same experimental 
conditions. A gold electrode was successfully used for the electrochemical qualita-
tive and quantitative determination of azithromycin dihydrate and azithromycin from 
capsules (Hemomycin®) and for the separation of azithromycin from one of the ex-
cipients, lactose monohydrate. The good catalytically activity of the gold electrode 
was employed only for the qualitative electrochemical determination of pure clari-
thromycin by appearance of one cathodic and four anodic reactions, which enabled 
structural changes in this molecule during electrochemical reactions to be studied. 
Commercial clarithromycin, Clathrocyn® was qualitative determined by one repro-
ducible anodic reaction. The activity of one of the excipients, Avicel, observed as a 
cathodic peak at different potential from the cathodic peak obtained with pure clari-
thromicin was used for the determination of its presence in Clathrocyn® tablets. 
FTIR Analysis showed the apparent changes in structure of pure clarithromycin, as 
well as in the molecule of clarithromycin in Clathrocyn® tablets. HPLC Analysis 
showed a significant decrease in the concentration of azithromycin, Hemomycin® 
clarithromycin and Clathrocyn® after the electrochemical reactions. 
Keywords: azithromycin, clarithromycin, gold electrode, cyclic voltammetry. 
INTRODUCTION 
Macrolide antibiotics are active on both gram-positive and, to a lesser extent, 
on gram-negative microorganisms. They exert their antimicrobial action by bin-
ding to the bacterial 50S ribosomal subunit and inhibiting ribosomal assembly 
and protein synthesis. Erythromycin is a natural compound metabolized by a strain 
of Streptomyces erythreus. As a broad-spectrum antibiotic, it has proved inva-
luable for the treatment of bacterial infections in patients with β-lactam hypersen-
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sitivity. From this parent macrolide, several derivatives have been synthesized. 
Beckmann rearrangement of the 9-oxime followed by reduction and methylation 
gives azithromycin, which shows good activity against gram-negative bacteria, 
including Haemophilus influenzae. If the 6-hydroxy group is methylated, clari-
thromycin is obtained, which has an improved pharmacokinetic profile compared 
to the parent molecule. Azithromycin has a methylated nitrogen atom at position 
number nine on the macrolide lactone ring, and clarithromycin has a methyloxyl 
substitution at position number six of the macrolide ring (Fig. 1). These modify-
cations affect the biological potency of the molecules, with azithromycin having 
a stronger affinity for ribosome and affecting equally the 50S ribosomal assem-
bly and protein elongation.1,2 Clarithromycin also affects both processes but at a 
concentration 10 times higher than that of azithromycin, and erythromycin inhi-
bits translation much more efficiently than the ribosomal assembly.2 
Fig. 1. Chemical structures of azithro-
mycin, erythromycin and clarithromycin. 
Azithromycin and clarithromycin present several clinical advantages over 
erythromycin, including better oral bioavailability, enhanced spectrum activity, 
higher tissue concentrations and improved tolerability.3 Clarithromycin is widely 
used for the eradication of Helicobacter pylori, which causes gastritis and gastric 
ulcers.4 Oral clarithromycin is used in combination with amoxicilin and lansopra-
zole or omeprazole (triple therapy) for the treatment of Helicobacter pylori infec-
tions and duodenal ulcers.5−7 Quantitative methods using high performance li-
quid chromatography (HPLC) procedures for the analysis of azithromycin and 
clarithromycin have been widely applied.8−11 Electrochemical methods for azi-
thromycin determination are promising, being the cheaper and faster. Studies on 
the electrochemical oxidation and determination of azithromycin on glassy car-
bon and modified glassy carbon electrodes have been frequently published in the 
last few years. Hitherto, voltammetric determinations of azithromycin, including 
its determination in pharmaceutical dosage forms have been published.12,13 In 
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the above-mentioned publications, the electrode material was usually glassy car-
bon, graphite and carbon paste or multi wall carbon nanotubes. 
The aim of the present study is to present the different reactivity of azithro-
mycin and clarithromycin (pure and commercial) in order to develop an electro-
chemical method for their qualitative and quantitative determination, as well as to 
separate or determine them in the presence of some excipient compounds in cap-
sule (tablets) form. The macrolide antibiotics were examined at a gold electrode 
in neutral electrolyte using cyclic linear sweep voltammetry under the same ex-
perimental conditions. HPLC and FTIR spectroscopy were used for the analysis 
of the bulk electrolyte after the electrochemical reactions. 
EXPERIMENTAL 
Azithromycin dihydrate and clarithromycin, kindly provided by Hemofarm (Vršac, Serbia), 
were examined separately as pure substances, without further purification, in one set of electroche-
mical experiments. A comparative study was performed with capsulated azithromycin, marketed by 
Hemofarm as Hemomycin®, which except azithromycin contains the excipients: sodium lauryl sul-
fate, magnesium stearate, lactose monohydrate and corn starch. A comparative study was also per-
formed with clarithromycin in tablet form, marketed by Hemofarm as Clathrocyn®, which in addi-
tion to pure clarithromycin contains the excipients: magnesium stearate, corn starch, Povidon 490, 
Avicel P401 and Prosolv SMC 90. The pure macrolide antibiotics and the content of the tablets 
(capsules) were added directly into the electrolytes in the concentrations given in detail in the Fig. 
captions. Before each measurement the electrolytes were purged with nitrogen for 20 minutes. 
The NaHCO3 used for the supporting electrolyte was of analytical grade (Merck). The solu-
tions were prepared with 18 MΩ water. Standard equipment and a three electrode electrochemical 
cell were used for the cyclic voltammetry measurements, as previously described in detail.14−18 
Polycrystalline gold (surface area 0.500 cm2), which served as the working electrode, was polished 
with diamond paste and cleaned with a mixture of 18 MΩ water and sulfuric acid. A platinum wire 
was used as the counter electrode and a saturated calomel electrode (SCE) as the reference elec-
trode. All the potentials are given vs. SCE. The electrode surface was controlled by cyclic voltam-
metry before each experiment. Prior to the control of the electrode surface and before the addition 
of the macrolide antibiotics, the electrolyte was purged with nitrogen. All the experiments were 
performed at room temperature. 
The pH of the electrolyte was measured using a PHM 93 reference pH meter, Radiometer, 
Copenhagen. 
The characteristics of the HPLC instrument are as follows: HPLC Instrument GBC, pump LC 
1120, UV VIS detector LC 1205, manual injector RHEODYNE 7725i, column Asahipak ODP-50 
(250 mm×4 mm), stationary phase L21 (USP-a rigid, spherical styrene–divinyl benzene copolymer, 
5 µm), mobile phase 0.002 M diammonium hydrogen phosphate, propanol-2, acetonitrile (pH 9.5, 
flow rate 1.0 cm3 min-1), wave length 215 nm. 
The IR spectra were obtained using a FTIR BOMEM MB 100 Hartmann Braun FTIR spectro-
meter. The samples were analyzed in the form of KBr pellets after removal of the liquid under high 
vacuum at low temperature. 
RESULTS AND DISCUSSION 
A polycrystalline gold electrode was selected as the optimal working electro-
de for the examination of pharmaceutical compounds because it is completely de-
fined with an always reproducible cyclic voltammogram and consequently, all 
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the electrochemical reactions at this electrode can be attributed only to the stu-
died molecule. In order to avoid the influence of organic molecules (with direct 
oxidation/reduction ability or adsorption ability at a gold electrode) arising from 
a solvent or a part of a buffer solution in the electrolyte and to obtain only the 
reactions of the pharmaceutical compounds, 0.05 M NaHCO3 was selected as the 
supporting electrolyte. 
Cyclic voltammetry investigations of pure azithromycine showed that the 
oxidative peak of pure azithromycin at 0.6 V in 0.05 M NaHCO3 at a scan rate of 
50 mV s−1 is a linear function of the concentration:14 
ipa (mA cm−2) = 0.023 (±0.0043) + 0.110 (±0.0099) c (mg cm−3), r = 0.9921 (1) 
Cyclic voltammograms presented in Fig. 2 show that for every investigated 
azithromycin dihydrate concentration only one very clear, wide and reproducible 
anodic peak was obtained in the concentration range 0.235–0.588 mg cm−3. It is 
to be mentioned that that there is no cathodic activity of azithromycin. 
 
Fig. 2. Anodic part of the cyclic voltammogram of an Au electrode in 0.05 M NaHCO3 (?) and with 
the addition of 0.235, 0.353, 0.471 and 0.588 mg cm-3 pure azithromycin dihydrate (full line); the 
lowest concentration is assigned by one arrow andthe highest with four arrows. Sweep rate 50 mV s-1. 
The anodic part of the cyclic voltammograms obtained with azithromycin in 
capsule form, Hemomycin®, is presented in Fig. 3, from which it is obvious that 
two peaks appeared. The peak at 0.6 V, which is the oxidative peak of pure azi-
thromycin is already observed in Fig. 2, but second peak at 0.4 V is the oxidative 
peak of the one excipient, lactose monohydrate. Sodium lauryl sulfate, magne-
sium stearate and corn starch are electrochemically totally inactive under the ap-
plied experimental conditions.14 Using the anodic behavior of azithromycin in 
capsule, Hemomycin®, shown in Fig 3, an electrochemical method for the sepa-
ration of azithromycin from lactose monohydrate at a gold electrode surface was 
developed. From the reproducible anodic peak at 0.4 V, lactose monohydrate is 
always recognized in the tested contents of capsule, which is important for the 
additional control of the contents of Hemomycin® capsules using a non time con-
suming and simple electrochemical method. 
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Fig. 3. Anodic part of the cyclic voltammogram of an Au electrode in 0.05 M NaHCO3 (?) and with 
addition of 0.235, 0.353, 0.471 and 0.588 mg cm-3 of Hemomycin® from capsules (full line), the 
lowest concentration is assigned by one arrow and highest with four arrows. Sweep rate 50 mV s-1. 
Each of the investigate concentrations of Hemomycin® gave a reproducible 
anodic oxidation peak and a linearity of the anodic peak current vs. concentration 
was obtained, as in the case of pure azithromycin. The linearity of the anodic 
peak current vs. concentration was obtained for lactose monohydrate in the in-
vestigated range of concentrations presented in Fig. 3, which opens the possibility 
for the development of a method for the quantitative detection of this compound. 
HPLC Analysis of the bulk of electrolyte confirmed the data obtained by 
analysis of the peak current values concerning the correlation with the investigate 
concentrations for azithromycin and Hemomycin®. 
Azithromycin has a methylated nitrogen atom at position nine on the macro-
lide lactone ring and clarithromycin has a methyloxyl substitution at position six 
of the macrolide ring (Fig. 1), which suggests possible different electrochemical 
activities of this two compounds. 
The anodic part of the cyclic voltammogram of pure clarithromycin is pre-
sented in Fig. 4, from which it can be seen that in the anodic direction, a small, 
wide and reproducible anodic peak appears at −0.58 V. 
Two reproducible anodic peaks were also observed at 0.10 V and at 0.33 V. 
In the region of AuO formation, a minor reproducible increase of the oxide peaks 
is seen. In this region the apparent activity of azithromycin (Fig. 2) can be used 
for its qualitative and quantitative determination. At –0.58 V in the anodic direc-
tion, azithromycin is not active and at 0.10 V and at 0.33 V, just a small increase 
of anodic currents is obvious, but there are no peaks (Fig. 2). 
In Fig. 5 it is shown that a reproducible cathodic peak was obtained with 
clarithromycin at −0.61 V. However, with clarithromycin none of the observed 
peaks are proportional to the concentration of the antibiotic in the range of 0.110– 
–0.625 mg cm−3, which is in accordance with the conclusion  that four reproduci-
ble anodic peaks and one cathodic peak only qualitatively determine clarithromycin.15 
In order to get insight in the structural changes in the clarithromycin mole-
cule during electrochemical reactions, electrochemical studies combined with the 
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analysis of the bulk electrolyte after the electrochemical reactions by FTIR spec-
troscopy and HPLC were performed. 
 
Fig. 4. Anodic part of the cyclic voltammogram of an Au electrode in 0.05 M NaHCO3 (?) and 
with the addition of 0.32 mg cm-3 of pure clarithromycin, (full line). Sweep rate 50 mV s-1. 
 
Fig. 5. Cathodic part of the cyclic voltammogram of an Au electrode in 0.05 M NaHCO3 (?) and 
with the addition of 0.32 mg cm-3 of pure clarithromycin, (full line). Sweep rate 50 mV s-1. 
The FTIR spectrum of pure clarithromycin and clarithromycin mixed with car-
bonates, both before the electrochemical experiment, served as reference for the 
further analysis. The observed changes in the molecule of clarithromycin were 
tracked with these data. The potential was held at selected values corresponding 
to all the observed current peaks (at −0.58 V, 0.10 V, 0.33 V and −0.61 V) for 4, 
8 and 10 h and two samples of the electrolyte were analyzed by FTIR spectro-
scopy and HPLC. Significant changes in the molecular structure of clarithromy-
cin were observed when the potential had been held at the potential of the ca-
thodic peak observed in Fig. 5 (–0.61 V) for 4 h,15 8 and 10 h. 
The FTIR spectrum reveals two obvious changes after holding the potential: 
the disappearance of the 1730 cm–1 peak corresponding to the carbonyl group vi-
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bration of the lactone, and an intense reduction of the 1170 cm–1 peak, probably 
corresponding to the C–O vibration in the lactone, which implies changes in the 
ester bond of the lactone. The disappearance of the carbonyl band at 1690 cm–1 
indicates a change in this group also. No absorptions were recorded in the 1000–
–1100 cm–1 range, which could be the result of changes in the ether and acetal 
bonds.15 When the potential was held at the cathodic peak potential observed in 
Fig. 5 (–0.61 V) for 8 and 10 h, the FTIR spectrum showed the same changes. 
The FTIR analysis did not reveal clear changes in the molecule structure 
after 4 and 10 h of holding the potential at 0.10V and at 0.33 V, except a minor 
reduction of the bands in the 1000–1100 cm–1 region. 
Cyclic voltammogram investigation of clarithromycin in tablets, Clathro-
cyn®, indicated a different behavior from the pure antibiotic and that observed 
activities can be attributed to the excipient Prosolv, as an anodic peak at 0.33 V 
and to the excipient Avicel, as a cathodic peak at −0.90 V, which could be im-
portant for the electrochemical control of theirs contents in Clathrocyn®,16 al-
though a concentration dependency of commercial clarithromycin and Avicel was 
not observed. 
The anodic part of the cyclic voltammogram of Clathrocyn® as presented  in 
Fig. 6, shows only one reproducible and characteristic, sharp anodic peak in the 
potential region from 0.60 V to 0.80 V in the range of concentrations 0.110– 
–0.725 mg cm−3. 
 
Fig. 6. Anodic part of the cyclic voltammogram of an Au electrode in 0.05 M NaHCO3 (?) and 
with addition of 0.56 mg cm-3 of Clathrocyn® (full line). Sweep rate: 50 mV s-1. 
In order to investigate the structural changes in the clarithromycin molecule in 
Clathrocyn® tablets caused by electrochemical processes, electrochemical studies 
combined with the analysis of the bulk electrolyte after the electrochemical re-
actions by Fourier transform infrared spectroscopy and high performance liquid 
chromatography were performed, similar to the investigation of pure clarithromycin.16 
The FTIR spectrum of the bulk electrolyte after cycling the potential, in the 
range presented in Fig. 6 for 8 h shows: the disappearance of the peak at 1730 cm−1 
1434 AVRAMOV IVIĆ, PETROVIĆ and MIJIN 
(carbonyl group of lactone) and the very small peak at 1170 cm−1 (C(O)−O−C 
vibrations of the lactone), indicating the disappearance of the lactone structure. 
Also, the reduction of intensity of the vibration band at 1695 cm−1 indicates 
changes of the carbonyl group at position 9 of the clarithromycin molecule in 
Clathrocyn® tablets. The same changes in the clarithromycin molecule in Cla-
throcyn® tablets were observed under the experimental conditions previously pu-
blished.16 As in the case of pure clarithromycin, this FTIR data combined with 
cyclic voltammetry can be helpful in the qualitative detection of the examined 
commercial clarithromycin. 
HPLC Analysis of the bulk of electrolyte (the potential was held for 4 h at 
the 0.10 V and 0.70 V) showed a significant decrease (40 %) of the concentration 
of clarithromycin, both pure and commercial, as a consequence of the electroche-
mical reactions which had occurred. 
Erithromycin was chosen as the macrolide antibiotic for the subject of the 
present studies because today it is the most safe antimicrobes drug and it was 
162nd of the top 300 prescribed drugs in the year 2005 (which includes different 
drugs, for example, drugs for neoplastic action (20) (FDA)),19 while azithromy-
cin was 176th in the year 2005.20 Cyclic voltammetry, HPLC and FTIR results 
with erithromycin suggest electrochemical activity similar to clarithromycin.20 
CONCLUSIONS 
In a conclusion, it should be pointed out that clarithromycin investigated 
under the same experimental conditions as azithromycin showed quite different 
behavior, which is attributed to the fact that azithromycin has a methylated nitro-
gen atom at position number nine on the macrolide lactone ring while clarithro-
mycin has a methyloxyl substitution at position number six of the macrolide ring. 
It was shown that a gold electrode can be successfully employed for the qua-
litative and quantitative electrochemical determination of azithromycin dihydrate 
and azithromycin from capsules (Hemomycin®) and for the separation of azithro-
mycin from lactose monohydrate. Lactose monohydrate can also be quanti-
tatively determined. 
The good catalytic activity of a gold electrode can be employed only for the 
qualitative electrochemical determination of pure clarithromycin by the appea-
rance of the one cathodic and four anodic reactions, which enables structural 
changes in this molecule during electrochemical reactions to be studied. FTIR 
analysis showed significant structural changes in the clarithromycin molecule, 
i.e., changes in the ester bond of the lactone and changes in the ether and acetal 
bonds. Clarithromycin in tablets, Clathrocyn®, is defined by one reproducible 
anodic peak and the activity of the excipient Avicel was used for the determi-
nation of its presence in Clathrocyn® tablets. FTIR analysis showed changes in 
the structure of the molecule indicating the disappearance of the lactone moiety 
and changes of carbonyl group at position 9. HPLC Analysis of the bulk elec-
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trolyte showed a significant decrease in the concentration of all the examined 
macrolide  antibiotics, as a consequence of the electrochemical reactions which 
had occurred. 
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И З В О Д  
ПРОУЧАВАЊЕ ЕЛЕКТРОХЕМИЈСКЕ АКТИВНОСТИ НЕКИХ МАКРОЛИДНИХ 
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М. Л. АВРАМОВ ИВИЋ1, С. Д. ПЕТРОВИЋ2,3 и Д. Ж. МИЈИН2 
1IHTM – Centar za elektrohemiju, Wego{eva 12, Beograd, 2Tehnolo{ko–metalur{ki fakultet, 
Karnegijeva 4, Beograd i 3Hemofarm grupa, Farmaceutska i hemijska industrija, Vr{ac 
У раду су приказани резултати испитивања електрохемијске активности азитромицина 
и кларитромицина (чисте супстанце и комерцијалног фармацеутског производа) на електро-
ди од злата у неутралном електролиту. HPLC и FTIR спектроскопија су коришћене за ана-
лизу електролита после електрохемијске реакције. Показано је да под истим експериментал-
ним условима азитромицин и кларитромицин испољавају потпуно различито електрохемиј-
ско понашање условљено разликама у структури макролидног прстена. Максимална вред-
ност висине јединог струјног врха оксидације чистог азитромицина и азитромицина у кап-
сули Хемомицина® на 0,6 V у 0,05 M NaHCO3 при 50 mV s-1 је линеарна функција концен-
трације у опсегу 0,235–0,588 mg cm-3 што је омогућило развијање методе за његово квали-
тативно и квантитативно одређивање. Развијена је и метода за сепарацију и квантитативно 
одређивање ексципиента, монохидрата лактозе. Квалитативно је одређен чист кларитроми-
цин детекцијом репродуктивне четири анодне и једне катодне реакције док је кларитроми-
цин у таблети, Clathrocyn®, квалитативно одређен једном репродуктивном анодном реакци-
јом. FTIR анализа је показала уочљиве промене у структури молекула кларитромицина. Та-
кође су уочене и структурне промене после испитивања кларитромицина у таблети Клатро-
цина®. HPLC анализа је указала на значајно смањење концентрација азитромицина, Хемо-
мицина®, кларитромицина и Клатроцина® у електролиту после електрохемијских реакција. 
(Примљено 8. октобра 2007) 
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